GSK Spinout NeRRe Begins with $19M, Neurokinin Drugs
By Nuala Moran
Friday, December 21, 2012
A third spinout has emerged from GlaxoSmithKline plc's neurosciences research portfolio, with the formation of NeRRe Therapeutics Ltd. The new company begins life with a portfolio of four neurokinin-1 receptor antagonists of which two are ready for Phase II.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.